SMN2 and proximal spinal muscular atrophy: Onasemnogene abeparvovec, an AAV-based therapy carrying a functional copy of the SMN gene, was approved in May 2019 as the first gene therapy for SMA in the United States and illustrates that AAV approaches can lead to clinical successes for devastating neurological diseases (Hoy, 2019).